Does PONATINIB Cause Second primary malignancy? 15 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Second primary malignancy have been filed in association with PONATINIB (Iclusig). This represents 0.2% of all adverse event reports for PONATINIB.
15
Reports of Second primary malignancy with PONATINIB
0.2%
of all PONATINIB reports
2
Deaths
6
Hospitalizations
How Dangerous Is Second primary malignancy From PONATINIB?
Of the 15 reports, 2 (13.3%) resulted in death, 6 (40.0%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PONATINIB. However, 15 reports have been filed with the FAERS database.
What Other Side Effects Does PONATINIB Cause?
Death (1,735)
Off label use (1,071)
Product dose omission issue (817)
Fatigue (687)
Rash (639)
Headache (553)
Pyrexia (542)
Nausea (466)
Hospitalisation (459)
Constipation (435)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which PONATINIB Alternatives Have Lower Second primary malignancy Risk?
PONATINIB vs PONATINIB\PONATINIB
PONATINIB vs PONESIMOD
PONATINIB vs PORACTANT ALFA
PONATINIB vs PORFIMER
PONATINIB vs POSACONAZOLE